Discovery of 4′-[(Imidazol-1-yl)methyl]biphenyl-2-sulfonamides as dual endothelin/Angiotensin II receptor antagonists
摘要:
A series of 4'-[(imidazol-1-yl)methyl]biphenylsulfonamides has potent antagonist activity against both angiotensin II AT(1) and endothelin ETA receptors. Such dual-acting antagonists could have utility in the treatment of hypertension, heart failure, and other cardiovascular diseases in a broad patient population. Certain compounds in the present series are orally active in a rat model of angiotensin II-mediated hypertension. (C) 2603 Elsevier Science Ltd. All rights reserved.
Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
申请人:——
公开号:US20020143024A1
公开(公告)日:2002-10-03
Novel biphenyl sulfonamide compounds which are combined angiotensin and endothelin receptor antagonists are claimed along with methods of using such compounds in the treatment of conditions such as hypertension and other diseases, as well as pharmaceutical compositions containing such compounds.
[EN] BIPHENYL SULFONAMIDES AS DUAL ANGIOTENSIN ENDOTHELIN RECEPTOR ANTAGONISTS<br/>[FR] BIPHENYL SULFONAMIDES UTILISES COMME DOUBLES ANTAGONISTES DES RECEPTEURS DE L'ANGIOTENSINE ET DE L'ENDOTHELINE
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2001044239A2
公开(公告)日:2001-06-21
Novel biphenyl sulfonamide compounds which are combined angiotensin and endothelin receptor antagonists are claimed along with methods of using such compounds in the treatment of conditions such as hypertension and other diseases, as well as pharmaceutical compositions containing such compounds.
ORAL FORMULATIONS OF DIPHENYLSULFONAMIDE ENDOTHELIN AND ANGIOTENSIN II RECEPTOR AGONISTS TO TREAT ELEVATED BLOOD PRESSURE AND DIABETIC NEPHROPATHY
申请人:Zhang Jinkun
公开号:US20140142149A1
公开(公告)日:2014-05-22
Methods of administering and pharmaceutical compositions of a biphenyl sulfonamide compound which is a dual angiotensin and endothelin receptor antagonist are disclosed for treating diseases.
A diphenylsulfonamide endothelin and angiotensin II receptor agonist to treat glomerulosclerosis
申请人:Ligand Pharmaceuticals Inc.
公开号:EP2732818A1
公开(公告)日:2014-05-21
Methods of administering and pharmaceutical compositions of a biphenyl sulphonamide compound which is a dual angiotensin and endothelin receptor antagonist are disclosed for treating diseases.
A DIPHENYLSULFONAMIDE ENDOTHELIN AND ANGIOTENSIN II RECEPTOR ANTAGONISTS TO TREATGLOMERULOSCLEROSIS
申请人:Ligand Pharmaceuticals Inc.
公开号:EP3222277A1
公开(公告)日:2017-09-27
Methods of administering and pharmaceutical compositions of a biphenyl sulphonamide compound which is a dual angiotensin and endothelin receptor antagonist are disclosed for treating diseases.